ASB Consultores’s Edwards Lifesciences EW Stock Holding History

ASB Consultores’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,475	Closed	-$237K	–	234
2024 Q1	$237K	Buy	+2,475	New	+$208K	0.06%	263
2022 Q2	–	Sell	-2,038	Closed	-$240K	–	194
2022 Q1	$240K	Buy	+2,038	New	+$229K	0.1%	183

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ASB Consultores's EW Position: Q2 2024 in Review

ASB Consultores sold out of Edwards Lifesciences (EW) in Q2 2024, closing a stake of 2,475 shares — an estimated $237K sold.

ASB Consultores first reported a position in EW in Q1 2022 and held it in 2 quarters. The position peaked at $240K in Q1 2022. 1,295 funds tracked by Wall St. Rank hold EW as of Q2 2024.

ASB Consultores reported no remaining Edwards Lifesciences position as of Q2 2024 after selling out during the quarter.
ASB Consultores sold 2,475 Edwards Lifesciences shares in Q2 2024, an estimated $237K.
ASB Consultores first reported a position in Edwards Lifesciences in Q1 2022 and held it in 2 quarters.
ASB Consultores's Edwards Lifesciences position peaked at $240K in Q1 2022.
1,295 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2024.

Based on ASB Consultores's 13F filing for Q2 2024, filed 12 Aug 2024.